Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation

Published:2015-09 Issue:14 Volume:16 Page:1585-1594
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Choi Boyoon¹,Kim Myeong Gyu¹,Han Nayoung¹,Kim Therasa²,Ji Eunhee³,Park Seonyang⁴,Kim In-Wha¹,Oh Jung Mi¹

Affiliation:

1. College of Pharmacy & Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea

2. College of Pharmacy, Chonnam National University, Gwangju, Korea

3. College of Pharmacy, Gachon University, Incheon, Korea

4. Department of Internal Medicine, Seoul National University Medicine of College, Seoul, Korea

Abstract

Aim: A population pharmacokinetic (PPK) analysis was conducted to describe the influence of GSTA1 polymorphisms on intravenous busulfan in adults undergoing allogeneic hematopoietic stem cell transplantation. Patients & methods: A PPK model was developed from 36 patients by a one-compartment model with first-order elimination. Results: The typical value of clearance and volume of distribution were 11.0 l/h and 42.4 l, respectively. Clearance decreased by 15% and area under the concentration-time curves (AUCs) increased with GSTA1 variants compared with wild-type (both p < 0.05). Subtherapeutic AUCs were seen only in wild-type patients. Conclusion: To our knowledge, this is the first PPK study to suggest that GSTA1 polymorphisms in adults are associated with busulfan PK.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.15.98

Reference54 articles.

1. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age

2. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2

3. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCT;Transplantation and Cellular Therapy;2023-12

2. Saliva as a noninvasive sampling matrix for therapeutic drug monitoring of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation: A prospective population pharmacokinetic and simulation study;CPT: Pharmacometrics & Systems Pharmacology;2023-07-25

3. Population Pharmacokinetic Model of Intravenous Busulfan in Hematopoietic Cell Transplantation: Systematic Review and Comparative Simulations;Clinical Pharmacokinetics;2023-07

4. Predicting busulfan exposure in patients undergoing hematopoietic stem cell transplantation using machine learning techniques;Expert Review of Clinical Pharmacology;2023-06-20

5. Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan;Bone Marrow Transplantation;2023-04-21